US Stock Insider Trading | MannKind Corporation Discloses One Insider Transaction on March 10

K-LinePoet · 2026-03-25T02:43:36+00:00

MannKind Corporation Biomedical recently disclosed insider trading activity. Director Castagna Michael bought 100,000 shares on March 10, 2026, at a price of $2.59 per share. Additionally, the company focuses on biopharmaceutical research and development for diabetes and cancer, with its main product AFREZZA being a super-rapid-acting insulin.

K-LinePoet

2026-03-25 02:43:36

Abstract generation in progress

On March 10, 2026, MannKind Corporation (MNKD) disclosed an insider trading activity. Director Michael Castagna purchased 100,000 shares.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Director	Michael Castagna	March 10, 2026	Buy	100,000	2.59	259,000
March 3, 2026	Executive	Christopher B. Prentiss	March 1, 2026	Buy	5,000	3.27	16,400
March 3, 2026	Director	Anthony C. Hooper, James Samuel Shannon	March 1, 2026	Buy	47,000	3.27	153,700
March 2, 2026	Director	Michael Castagna	March 1, 2026	Buy	15,300	3.27	50,000
March 2, 2026	Executive	Stuart A. Tross	March 1, 2026	Buy	15,300	3.27	50,000
January 9, 2026	Executive	Stuart A. Tross	January 8, 2026	Sell	47,000	6.33	297,500
December 19, 2025	Director	Michael Castagna	December 17, 2025	Buy	65,800	4.55	295,400
December 19, 2025	Director	Michael Castagna	December 17, 2025	Sell	65,800	6.01	395,500
December 16, 2025	Director	Michael Castagna	December 16, 2025	Sell	42,100	6.00	252,700
December 16, 2025	Director	Michael Castagna	December 16, 2025	Buy	42,100	4.55	191,600

【Company Profile】

MannKind Corporation was incorporated on February 14, 1991, in Delaware, USA. MannKind is a biopharmaceutical company focused on developing, manufacturing, and marketing therapies and drugs such as those for diabetes and cancer. The company’s leading candidate product—AFREZZA inhalable powder—is a ultra-rapid-acting insulin currently in late-stage clinical trials for the treatment of hyperglycemia in adults with type 1 or type 2 diabetes. AFREZZA uses proprietary technology to load insulin molecules into inhalable particles. When aerosolized and inhaled through the AFREZZA inhaler, these particles reach the lungs. Diabetes is a major health issue.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.